Rhenman & Partners Asset Management AB Trims Stake in Repligen Co. (NASDAQ:RGEN)

Rhenman & Partners Asset Management AB reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 10.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 9,000 shares of the biotechnology company’s stock after selling 1,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Repligen were worth $1,295,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. UMB Bank n.a. raised its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Repligen in the 4th quarter valued at approximately $216,000. Worldquant Millennium Advisors LLC raised its holdings in shares of Repligen by 11.9% in the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock worth $7,482,000 after buying an additional 5,337 shares during the last quarter. Van ECK Associates Corp raised its stake in Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after acquiring an additional 3,066 shares during the last quarter. Finally, Stephens Investment Management Group LLC lifted its holdings in shares of Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after purchasing an additional 37,057 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Down 8.0 %

Repligen stock opened at $111.94 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $6.29 billion, a PE ratio of -219.49, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a fifty-two week low of $106.78 and a fifty-two week high of $182.52. The firm has a 50 day moving average price of $150.03 and a 200 day moving average price of $147.51.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Research analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RGEN. Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $178.64.

Insider Activity

In other Repligen news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.